Retatrutide (Triple Receptor Agonist)

May 28, 2026 — Eli Lilly and Company announced it will present new cardiometabolic data at the American Diabetes Association’s 86th Scientific Sessions (June 5–8, New Orleans) and host an investor event June 6 (6:00 p.m. CDT).

Key clinical updates include pivotal Phase 3 results for investigational retatrutide (once-weekly GIP/GLP‑1/glucagon triple agonist): TRIUMPH‑1 showed up to 70.3 lb (28.3%) mean weight loss at 80 weeks in adults with obesity; TRANSCEND‑T2D‑1 showed A1C reductions up to 2.0% and weight loss up to 36.6 lb (16.8%) at 40 weeks in type 2 diabetes.

Lilly will also present Phase 3 ACHIEVE program results for Foundayo (orforglipron), described as an oral GLP‑1 without food/water restrictions: ACHIEVE‑2 reduced A1C up to 1.7% vs 0.8% with dapagliflozin (40 weeks); ACHIEVE‑3 was superior to oral semaglutide with better A1C and 73.6% greater relative weight loss (52 weeks); ACHIEVE‑5 reduced A1C up to 2.1% vs 0.8% with placebo added to insulin glargine (40 weeks). Additional ATTAIN analyses reported >14% weight reduction in peri-/post-menopausal women and improved insulin sensitivity markers.